Last Minute Allocation Shake Up? Pfizer’s One-Dose Data Could Change COVID-19 Vaccine Rollout

 
• By Sarah Karlin-Smith

New data released ahead of 10 December advisory committee is raising questions about whether the US government’s plan to hold back doses of Pfizer/BioNTech’s vaccine is the right move. Still, most experts don’t expect this to be a one-and-done vaccine. But testing the hypothesis might help FDA solve its dilemma on when to vaccinate placebo patients.

illustration from Pfizer briefing document and photo by Dan Kitwood/Getty Images
Pfizer likely needs more data to bring the efficacy of a single dose of its COVID-19 vaccine into focus, but such a study could solve the dilemma of what to do with patients in the placebo arm of the trial. • Source: illustration from Pfizer briefing document and photo by Dan Kitwood/Getty Images

More from US FDA Performance Tracker

More from Regulatory Trackers